March 2016, Vol 9, Seventh Annual Payers' Guide

Drug Updates, FDA Approvals, Payers' Guide

Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma

Drug Updates, FDA Approvals, Payers' Guide

Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer

Drug Updates, FDA Approvals, Payers' Guide

Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia

Drug Updates, FDA Approvals, Payers' Guide

Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus

Lisa A. Raedler, PhD, RPh

1
2
3
4
5

Page 4 of 5
Results 31 - 40 of 43

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Special Print Editions

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.